Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Combination Proof-of-Concept Phase 2 Clinical Trial of AB-729 in Combination with AB-506 in Subjects with Chronic Hepatitis B

Trial Profile

A Combination Proof-of-Concept Phase 2 Clinical Trial of AB-729 in Combination with AB-506 in Subjects with Chronic Hepatitis B

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AB-506 (Primary) ; AB-729 (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions; Proof of concept
  • Sponsors Arbutus Biopharma
  • Most Recent Events

    • 03 Oct 2019 According to an Arbutus Biopharma media release, the company announced to discontinue the clinical development of AB-506 due to two cases of acute hepatitis in phase 1a portion of the trial ACTRN12618000987268.
    • 03 Oct 2019 Status changed from planning to withdrawn prior to enrolment, according to an Arbutus Biopharma media release.
    • 05 Aug 2019 According to an Arbutus Biopharma media release, the company anticipate moving into this combination proof-of-concept phase 2 clinical trial in subjects with chronic hepatitis B in the second half of 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top